Get the Stockscreener App
1.26
12.50%
-0.18
After Hours:
1.26
Silexion Therapeutics Corp stock is traded at $1.26, with a volume of 1.35M.
It is down -12.50% in the last 24 hours and down -40.00% over the past month.
Silexion Therapeutics Corp is a developmental-stage company dedicated to the development of treatments for pancreatic cancer. The company is focused on enhancing its first-generation product (LODERTM ) to develop a newly formulated product to improve the clinical efficacy against pancreatic cancer.
See More
Previous Close:
$1.44
Open:
$1.41
24h Volume:
1.35M
Relative Volume:
0.13
Market Cap:
$5.25M
Revenue:
-
Net Income/Loss:
$-16.42M
P/E Ratio:
-0.054
EPS:
-23.3189
Net Cash Flow:
$-6.75M
1W Performance:
-33.68%
1M Performance:
-40.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$1.26
$1.45
1-Week Range:
$1.20
$1.7399
52-Week Range:
$0.575
$23.13
Silexion Therapeutics Corp Stock (SLXN) Company Profile
Name
Silexion Therapeutics Corp
Sector
Industry
Phone
972-8-6286005
Address
12 ABBA HILLEL ROAD, RAMAT GAN
Compare SLXN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLXN
Silexion Therapeutics Corp
|
1.26 | 5.25M | 0 | -16.42M | -6.75M | -23.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.32 | 122.13B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
710.00 | 78.30B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
646.64 | 39.73B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
276.19 | 35.50B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.61 | 28.47B | 3.30B | -501.07M | 1.03B | -2.1146 |
Silexion Therapeutics Corp Stock (SLXN) Latest News
The time has not yet come to remove your chips from the table: Silexion Therapeutics Corp (SLXN) - SETE News
How analysts predict Silexion Therapeutics Corp (SLXN) will perform this quarter? - US Post News
Biotech Alert: Searches spiking for these stocks today - TipRanks
Silexion Therapeutics announces exercise of warrants for $3.3M gross proceeds - MSN
3 Penny Stocks to Watch Now, 1/30/25 - TipRanks
Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds - GlobeNewswire
Cancer Drug Developer Silexion Raises Millions in Clever Financial MoveHere's the Deal - StockTitan
Stock market news: Signing Day Sports +124.23%, Silexion Therapeutics +80.74% among top gainers during mid day trading - Business Upturn
Stock market today: Signing Day Sports +200.52%, Silexion Therapeutics +69.63% among top gainers in early trading - Business Upturn
PESG Report: Silexion Therapeutics’ Systemic Delivery Breakthrough Positions Company as Rising Star in The Multi-Billion Dollar Precision Oncology Market - Yahoo Finance
Silexion (SLXN) Stock Rallies In Pre-Hour Market Amid Promising Study Results - Stocks Telegraph
US Futures Point To Cautious Start As Investors Await Fed's Rate Decision: Tesla, Microsoft, Meta Among Stocks In Focus Ahead Of Earnings - Benzinga
Why F5 Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket - Benzinga
Silexion reports breakthrough in KRAS cancer therapy By Investing.com - Investing.com Canada
Why Is Silexion Therapeutics Stock Soaring Over 100% On Tuesday? - AOL
Gold Gains 1%; Boeing Shares Rise Following Q4 Results - Benzinga
Nasdaq Surges More Than 300 Points; Lockheed Martin Shares Dip After Q4 Results - Benzinga
Silexion Therapeutics Surge in Recent Trading Amid 'Promising' Preclinical Data From Tumor Drug Candidate - Marketscreener.com
Silexion reports breakthrough in KRAS cancer therapy - MSN
Dow Gains Over 50 Points; General Motors Posts Upbeat Earnings - Benzinga
Silexion Therapeutics reports preclinical data for SIL-204 - TipRanks
Silexion Therapeutics Reports Strong Tumor Growth Reduction - GlobeNewswire
Revolutionary Cancer Treatment Cuts Tumors in Half: Silexion's New Drug Targets Multiple KRAS Mutations - StockTitan
TSMC Leads Pre-Market Gains After Record Q4 Earnings; Other Stocks See Volatility - HPBL
SLXN stock touches 52-week low at $0.82 amid sharp annual decline - Investing.com Australia
Silexion Therapeutics drops 18%, prices $5M share offering - MSN
Silexion Stock Hits Record Intraday Low After Pricing $5M Offering, But Retail Excitement Over Cancer Data Endures - MSN
Silexion Therapeutics Highlights New Preclinical Data From Its Pancreatic Cancer Studies - Benzinga
Silexion Stock Hits Record Intraday Low After Pricing $5M Offering, But Retail Excitement Over Cancer Data End - Asianet Newsable
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Why Taiwan Semiconductor Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket - Benzinga
Silexion Therapeutics Raises $5M in Public Offering to Advance RNA Cancer Therapies - StockTitan
Silexion Therapeutics Announces Pricing of $5.0 Million Public Offering - GlobeNewswire
Stocks to Watch: Serina Therapeutics, Powell Max, Silexion Therapeutics - MarketWatch
Silexion Therapeutics Shares Jump After Pancreatic-Cancer Treatment Data - MarketWatch
Silexion Shares Rise Late Following Pretrial Data From Pancreatic Cancer Treatment Showing Efficacy - Marketscreener.com
Silexion Therapeutics announces new preclinical results for SIL-204 - TipRanks
Silexion Therapeutics Announces Additional Promising - GlobeNewswire
Silexion's New Cancer Drug Shows Powerful Synergy with Chemo in Pancreatic Cancer Study - StockTitan
Silexion Therapeutics to Present SIL-204 Data in - GlobeNewswire
Silexion Therapeutics to Present SIL-204 Data in KRAS-Driven Pancreatic Cancer at the 2025 ASCO Gastrointestinal Cancers Symposium - Yahoo Finance
Pre-market Movers: AVGR, TIVC, ATNF, SLGL... - RTTNews
SLXN stock touches 52-week low at $1.82 amid market challenges - Investing.com
BioLineRx Announces $10 Million Registered Direct Offering - Quantisnow
Why Sangamo Therapeutics Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Silexion Therapeutics, Evonik collaborate on siRNA formulation development - Yahoo Finance
Silexion Therapeutics Corp Stock (SLXN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.09%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):